Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Monday, December 05, 2022Pfizer Inc and BioNTech SE announced that the companies have submitted an application to the US Food and Drug Administration FDA for emergency use authorization EUA of their Omicron BABAadapted bivalent COVID vaccine as the third g dose in the threed...
Bactobio Raises £6 Million To Discover Novel Antimicrobials
Monday, December 05, 2022Bactobio Ltd a biotechnology company uncovering safer and greener antimicrobial solutions from previously unexplored microbes announced today that it has closed an oversubscribed million bridge financing round The financing was led by Bridford Group...
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
Friday, December 02, 2022Innocan Pharma Corporation a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC Benitz Consulting to assi...
Aptamer Group announces new deals to support novel therapies and improved assays
Friday, December 02, 2022Aptamer Group plc the developer of novel Optimer binders to enable innovation in the life sciences industry announces a selection of new contract wins where Optimer technology is being explored by partners to offer new strategies for therapeutics and...
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
Thursday, December 01, 2022AbCellera and Rallybio Corporation announced today that they have entered into a strategic alliance to discover develop and commercialize novel antibodybased therapeutics for rare diseases This multiyear multitarget collaboration will combine AbCelle...
Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments
Wednesday, November 30, 2022Liminatus Pharma LLC a clinicalstage biopharmaceutical company developing novel immunemodulating cancer therapies and Iris Acquisition Corp Iris Nasdaq IRAA a publicly traded special purpose acquisition company SPAC formed for the purpose of acquirin...
Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic
Wednesday, November 30, 2022Ferring Pharmaceuticals today announced the US Food and Drug Administration FDA approved REBYOTA fecal microbiota livejslm a novel firstinclass microbiotabased live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile...
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
Tuesday, November 29, 2022Zymeworks Inc a clinicalstage biopharmaceutical company developing multifunctional biotherapeutics today announced that the waiting period under the HartScottRodino HSR Antitrust Improvements Act of as amended for the previously announced license ag...
AstraZeneca earns the Best Place to Work Certification across its operations in North Africa and Levant
Monday, November 28, 2022AstraZeneca an affiliate of the multinational pharmaceutical and biotechnology company has been recently recognized as one of the best places to work in North Africa and Levant for AstraZeneca outperformed the employee experience index with its uniq...
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
Monday, November 28, 2022XORTX Therapeutics Inc a latestage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is pleased to announce the successful screening and enrollment of the last remaining subjects into the X...
